Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRNX |
---|---|---|
09:32 ET | 2336 | 51.47 |
09:34 ET | 394 | 51.47 |
09:38 ET | 300 | 51.65 |
09:39 ET | 100 | 51.595 |
09:41 ET | 1593 | 51.655 |
09:45 ET | 500 | 51.4 |
09:48 ET | 200 | 51.29 |
09:50 ET | 418 | 51.36 |
09:52 ET | 349 | 51.49 |
09:54 ET | 200 | 51.33 |
09:56 ET | 3362 | 51.1 |
09:57 ET | 100 | 51.05 |
09:59 ET | 1500 | 50.96 |
10:01 ET | 100 | 51.04 |
10:03 ET | 1170 | 51.34 |
10:06 ET | 208 | 51.225 |
10:08 ET | 685 | 51.205 |
10:10 ET | 1200 | 51.46 |
10:12 ET | 400 | 51.58 |
10:14 ET | 300 | 51.67 |
10:15 ET | 3933 | 51.68 |
10:17 ET | 100 | 51.68 |
10:19 ET | 600 | 51.765 |
10:21 ET | 6170 | 51.905 |
10:24 ET | 2446 | 51.84 |
10:26 ET | 300 | 51.94 |
10:28 ET | 600 | 51.89 |
10:30 ET | 1400 | 51.85 |
10:32 ET | 1340 | 51.91 |
10:33 ET | 802 | 51.99 |
10:35 ET | 100 | 52.03 |
10:37 ET | 3201 | 51.96 |
10:39 ET | 1239 | 52.1 |
10:42 ET | 1600 | 52.23 |
10:44 ET | 1035 | 52.345 |
10:46 ET | 350 | 52.38 |
10:48 ET | 150 | 52.38 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Crinetics Pharmaceuticals Inc | 4.2B | -13.9x | --- |
Immunovant Inc | 4.2B | -15.0x | --- |
Madrigal Pharmaceuticals Inc | 4.5B | -8.3x | --- |
Biohaven Ltd | 4.6B | -5.4x | --- |
BridgeBio Pharma Inc | 4.7B | -9.5x | --- |
Dyne Therapeutics Inc | 3.5B | -9.7x | --- |
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-3.77 |
Book Value | $7.91 |
P/E Ratio | -13.9x |
Price/Sales (TTM) | 3,000.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -20,068.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.